NCT01438216

Anidulafungin Pharmacokinetics in Intensive Care Unit Patients

Anidulafungin Population Kinetics in the Intensive Care Population

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Amsterdam UMC, location VUmc · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the pharmacokinetics of anidulafungin in intensive care patients.

Detailed description

Not a lot is known about the pharmacokinetic profile of anidulafungin in IC-patients. IC-patients are at high(er) risk for getting a systemic mould/yeast infection. Anidulafungin is a safe echinocandin with, so far, no reported interactions and few adverse effects. Due to this, anidulafungin is used more often on IC-wards. It is part of the national (Netherlands) IC sepsis protocol. The factors that influence the pharmacokinetics of anidulafungin in IC-patients has not been studied yet. Because these factors are unknown for this population, it is necessary for this research to be done. Any patient with an (suspected) invasive candidiasis whom is treated with anidulafunging can be includen. 20 patients will be included from 2 different university hospital (10 each). Samples will be taken on different days and timepoints, troughlevels on all treatment days and on treatment day 3 and 7 more samples will be taken voor AUC calculations.

Conditions

• Invasive Candidiasis
• Candidemia

Timeline

• Start date: 2011-09-01
• Primary completion: 2012-02-01
• Completion: 2012-03-01
• First posted: 2011-09-22
• Last updated: 2011-09-22

Locations

2 sites across 1 country: Netherlands